| Document |
Document Title |
|
WO/2020/229761A1 |
The invention relates to a pharmaceutical composition, comprising at least one compound of the echinocandin family and at least one other therapeutically active ingredient except for hypouricemic compounds, intended to be used as a cytop...
|
|
WO/2020/204507A1 |
The present invention relates to a composition for healing after rotator cuff repair, and more specifically, to a composition comprising teriparatide as an effective component for healing suture tears after rotator cuff repair. The compo...
|
|
WO/2020/173484A1 |
Disclosed are an anterior chamber perfusate for intraocular surgery and a use thereof; under the effect of balanced intraocular pressure, also containing a certain amount of L-alanyl-L-glutamine. Extracapsular cataract extraction, intrao...
|
|
WO/2020/162580A1 |
The present invention relates to a pharmaceutical composition containing mesenchymal stem cells to be administered to a patient who has undergone stent implantation. Specifically, the present invention relates to: a pharmaceutical compos...
|
|
WO/2020/144378A1 |
The present invention relates to the use of SGLT-2 inhibitors and/or an interleukin- 1-receptor antagonist or a non-agonist antibody reactive to IL-1 or IL-1R in the treatment of prevention of symptomatic hypoglycaemia after bariatric su...
|
|
WO/2020/121290A1 |
Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 μΜ to 1 mM; and (ii)...
|
|
WO/2020/121289A1 |
Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of between about 5 mg/ml to about 30 mg/ml, and having a total protein conc...
|
|
WO/2020/087181A1 |
Disclosed herein are matrices, compositions and methods of making matrices. The matrix comprises a biomolecule and the matrix is a dried, cross-linked foam. The matrix is not lyophilized. The method comprises foaming the composition, cro...
|
|
WO/2020/081817A1 |
The present disclosure includes composite microparticles for magnetically triggered release of a biologically active agent. Also included are systems including the biocompatible composite microparticles and an alternating current (AC) ma...
|
|
WO/2020/067439A1 |
The purpose of the present invention is to provide: a method for producing a high-quality graft, such as a sheet-shaped cell culture, that includes a variety of iPS cell-derived cells, such as cardiomyocytes, while possessing the functio...
|
|
WO/2020/027686A1 |
This invention relates to experimental medicine, and specifically to experimental gastroenterology, and may be used to prevent entero-entero anastomotic leaks. A method of preventing entero-entero anastomotic leaks comprising action usin...
|
|
WO/2020/019080A1 |
Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan composit...
|
|
WO/2020/019077A1 |
Low endotoxin fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising less than about 0.2, 0.18, 0.1, 0.01, 0.001, or 0.0005 endotoxin units (EU) per milligram of the fucan are di...
|
|
WO/2020/019081A1 |
A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose...
|
|
WO/2020/019078A1 |
High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60 % w/w of th...
|
|
WO/2020/019079A1 |
Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan composit...
|
|
WO/2020/005785A1 |
The subject invention provides materials and methods for reducing the amount of bioavailable pyrogens in a subject's body. Advantageously, by applying a composition comprising chlorhexidine gluconate to a site in a subject's body, for ex...
|
|
WO/2019/227122A1 |
A method of enhancing embryo implantation in a subject is disclosed which comprises administering to the uterine cavity of the subject a formulation comprising copper and/or zinc in an amount effective to stimulate endometrial production...
|
|
WO/2019/153099A1 |
The invention relates to a compound and procedure for optimising the transplant of vascularised solid organs and reducing the dysfunction of same, which comprises 400 to 1000 mg of alpha lipoic acid (ALA), preferably 600 mg of ALA, and t...
|
|
WO/2019/134725A2 |
According to the invention, a medicament is disclosed, a.) containing carboxymethylated starch and b.) containing a citrate and/or citric acid for reducing post-operative adhesions.
|
|
WO/2019/135136A1 |
A bi-coordinated silver (I) complex has antimicrobial activity and general formula Na+ 2[Ag+(L2-)(M2-)], wherein L is a ligand consisting of 2-mercaptobenzoic acid and M is a ligand different from said ligand L and consisting of 2-hydrox...
|
|
WO/2019/135729A1 |
A composition for aesthetic injections is intended for facial contouring, as well as for improving the condition of mucosa and skin on other parts of the body. The composition for aesthetic injections contains calcium hydroxyapatite and,...
|
|
WO/2019/122157A1 |
The invention refers to a lyophilisate comprising esmolol, adenosine and at least one pharmaceutical salt and its use in cardioplegia.
|
|
WO/2019/121488A1 |
The present invention provides nitric oxide releasing hyaluronic acid derivatives of formula (I) in which the carboxylic groups of the hyaluronic acid are partially esterified with a group capable to release nitric oxide: (I) The hyaluro...
|
|
WO/2019/108072A1 |
In one aspect, the present invention provides a composition comprising zebularine, a nucleotide inhibitor of DNA methyltransferase, optionally in combination with retinoic acid, and said composition for use in promoting complex tissue re...
|
|
WO/2019/078344A1 |
Post-surgical adhesion at an invasive site and migration of neutrophils to an invasive surgical site are prevented by administering an anti-IL-6 receptor antibody and/or a neutrophil neutralizing antibody.
|
|
WO/2019/078246A1 |
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as an IDO/TDO inhibitor. The compound represented by formula (I) or a pharmaceutically acceptable salt thereof can, for exam...
|
|
WO/2019/071902A1 |
Provided is a use of miR-21 in the prepartion of therapeutic drugs or diagnostic reagents for intrauterine adhesion and/or thin endometrium.
|
|
WO/2019/016572A1 |
A compound for use in the treatment or prevention of acute or chronic inflammatory disorders wherein the compound is a compound of Formula 1 : or a salt thereof, wherein n is 2-5, and R1 and R2 are independently selected from H or C1-C4 ...
|
|
WO/2018/231089A1 |
Field of use: The invention relates to organic and bio-organic combinatorial chemistry, specifically to new combinatorial libraries of polysaccharide derivatives and to supramolecular structures based thereon, which have high biological ...
|
|
WO/2018/217088A1 |
A staining composition is provided with improved staining intensity. The composition comprises a vital dye and hyaluronic acid, wherein the vital dye comprises Chicago Sky Blue and Trypan Blue. The staining composition is used to stain t...
|
|
WO/2018/217897A1 |
Disclosed herein is an immunogenic comprising an antigen and optionally IL-12. Also disclosed herein is a method for administering the vaccine through intradermal electroporation.
|
|
WO/2018/200739A1 |
The present disclosure provides methods and compositions for the treatment and prevention of infections and biofilm prevention during breast augmentation procedures. The present disclosure also provides methods and compositions for the p...
|
|
WO/2018/152592A1 |
The present disclosure relates to methods and products for reducing adhesions. In certain embodiments, the present disclosure provides a method of reducing adhesions in a subject, the method comprising exposing a region in the subject su...
|
|
WO/2018/144637A1 |
Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol...
|
|
WO/2018/143115A1 |
Provided is a bioabsorbable stent that has adequate strength, is highly robust and flexible, and has excellent expandability. This bioabsorbable stent is characterized in that a plurality of first tubular units in which a plurality of su...
|
|
WO/2018/134621A1 |
A composition for aiding the removal of polyps, in the form of a submucosal injectable formulation, comprising one or more salts of hyaluronic acid, saline solution and indigo carmine, but not including a substance exhibiting an angioton...
|
|
WO/2018/115800A1 |
The invention relates to a pharmaceutical composition comprising between 10 and 30 g/L fibrinogen, between 10 and 300 mM arginine, and between 10 and 300 mM glutamate. In addition, the composition has a pH of between 6 and 8.
|
|
WO/2018/094470A1 |
The present invention relates generally to methods and compositions for reducing the side effects of neuroexcitation associated with general anaesthetic agents by using cannabinoid- 1 receptor antagonists (CB IR) or inverse agonists. The...
|
|
WO/2018/062464A1 |
Provided is an anti-conglutination material that has an operability that allows reliable attachment thereof to biological tissue and in which tissue adhesiveness and biodegradability are improved. The anti-conglutination material has a w...
|
|
WO/2018/043731A1 |
The present invention relates to an anti-adhesion agent containing an emulsion composition that contains a lipid compound represented by general formula (I), an oil component and a surfactant in an aqueous phase. (In the formula, each of...
|
|
WO/2018/019244A1 |
The present invention relates to salts of 2,6-dimethylpyrimidone derivative and uses of the salts. The present invention also relates to a pharmaceutical composition comprising the salts or a combination thereof, and uses of the salts or...
|
|
WO/2018/014894A1 |
The invention relates to a medicament which a.) contains or even consists of carboxymethylated starch and/or b.) contains or even consists of epichlorohydrin-modified starch for the treatment of anastomoses.
|
|
WO/2017/153889A1 |
The present invention relates to a method of accelerating stem cell engraftement in a patient in need of hematopoietic stem cell transplantation.
|
|
WO/2017/147058A1 |
Methods of treating ischemic tissue injury or kidney disease, e.g., delayed graft function, that include administering a Nicotinamide adenine dinucleotide (NAD)/niacinamide (NAM) pathway agonist.
|
|
WO/2017/130802A1 |
The present invention addresses the problem of providing a cell sheet composition for healing or preventing discharge from a wounded region of a luminal organ. The present invention also addresses the problem of providing a method in whi...
|
|
WO/2017/123653A1 |
Disclosed herein are pharmaceutical compositions useful for the treatment and prevention of adhesions and ileus.
|
|
WO/2017/114902A1 |
There is provided a method of decellularizing adipose tissue comprising the steps of: a) Laminating the adipose tissue;b) Treating the adipose tissue resulting from step a) with a lipoprotein lipase at 32-42 degrees Celsius and at a conc...
|
|
WO/2017/082840A1 |
The present invention relates to the use of a zeolite as a chemical agent with additional cytotoxic effects used in pleurodesis in the cases of liquid accumulation (pleural effusion) or air accumulation (pneumothorax) in the pleural cavi...
|
|
WO/2017/078563A1 |
The present invention relates to medical biotechnology and cell technology. Proposed is a method for isolating stromal vascular fraction of adipose tissue, which includes: decantation of a lipoaspirate; delicate washing of the lipoaspira...
|
